780 reports of this reaction
11.2% of all ATAZANAVIR SULFATE reports
#2 most reported adverse reaction
DEPRESSION is the #2 most commonly reported adverse reaction for ATAZANAVIR SULFATE, manufactured by Aurobindo Pharma Limited. There are 780 FDA adverse event reports linking ATAZANAVIR SULFATE to DEPRESSION. This represents approximately 11.2% of all 6,992 adverse event reports for this drug.
Patients taking ATAZANAVIR SULFATE who experience depression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEPRESSION is a frequently reported adverse event for ATAZANAVIR SULFATE, accounting for a significant proportion of all reports.
In addition to depression, the following adverse reactions have been reported for ATAZANAVIR SULFATE:
The following drugs have also been linked to depression in FDA adverse event reports:
DEPRESSION has been reported as an adverse event in 780 FDA reports for ATAZANAVIR SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEPRESSION accounts for approximately 11.2% of all adverse event reports for ATAZANAVIR SULFATE, making it one of the most commonly reported side effect.
If you experience depression while taking ATAZANAVIR SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.